MeSH D004828 - partial epilepsies
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D004827:Epilepsy
D004828:Â
Partial epilepsies
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Abon Pharmaceuticals | Gabapentin | Gabapentin |  | 2024-09-09 |  |  |
| Accord Healthcare | Levetiracetam | Levetiracetam |  | 2011-02-14 |  |  |
| Levetiracetam | Levetiracetam Accord |  | 2011-10-03 |  |  | |
| Topiramate | Topiramate |  | 2009-03-27 |  |  | |
| Lacosamide | Lacosamide |  | 2022-07-12 |  |  | |
| Lacosamide | Lacosamide Accord |  | 2017-09-18 |  |  | |
| Acella Pharmaceuticals | Gabapentin | Gabapentin |  | 2012-05-01 |  |  |
| Ajanta Pharma | Lamotrigine | Lamotrigine |  | 2021-01-19 |  |  |
| Topiramate | Topiramate |  | 2023-08-15 |  |  | |
| Oxcarbazepine | Oxcarbazepine |  | 2024-02-22 |  |  | |
| Alembic Pharmaceuticals | Lamotrigine | Lamotrigine |  | 2011-01-13 |  |  |
| Levetiracetam | Levetiracetam |  | 2013-05-09 |  |  | |
| Lacosamide | Lacosamide |  | 2022-03-17 |  |  | |
| Alkem Laboratories | Gabapentin | Gabapentin |  | 2010-12-17 |  |  |
| Lamotrigine | Lamotrigine |  | 2013-06-14 |  |  | |
| Levetiracetam | Levetiracetam |  | 2022-05-27 |  |  | |
| Topiramate | Topiramate |  | 2023-06-20 |  |  | |
| Lacosamide | Lacosamide |  | 2022-05-19 |  |  | |
| Oxcarbazepine | Oxcarbazepine |  | 2023-03-18 |  |  | |
| Allergan | Gabapentin | Gabapentin |  | 2003-09-12 |  |  |
| Lamotrigine | Lamotrigine |  | 2009-01-22 |  |  | |
| Levetiracetam | Levetiracetam |  | 2009-03-02 |  |  | |
| Levetiracetam | Levetiracetam Actavis |  | 2011-10-03 |  |  | |
| Levetiracetam | Levetiracetam Actavis Group |  | 2011-12-04 |  |  | |
| Topiramate | Topiramate |  | 2009-03-27 |  |  | |
| Lacosamide | Lacosamide |  | 2023-01-05 |  |  | |
| Almatica Pharma | Gabapentin | Gralise | 2022-10-25 | 2011-01-28 |  |  |
1
2
3
4
5
6
...
15
>
Clinical Trials
Historical Success Rate
Phase 1
88%7/8
Phase 2
43%10/23
Phase 3
89%31/35
Approved: 20Overall Success rate: 34%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
...
10
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use